Singapore handles orphan drug registration through the Health Sciences Authority (HSA), which offers a special Orphan Drug Designation pathway. This process provides regulatory support and incentives, such as fee waivers and expedited review, to encourage the development and availability of treatments for rare diseases affecting small patient populations.